Instil Bio, Inc. (NQ:TIL)

7.220 UNCHANGED

Delayed Quote Updated: 10:29 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Instil Bio, Inc.

< Previous 1 2 3 4 5 6 Next >

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025

From Instil Bio

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 25, 2025

Via Benzinga

Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 04, 2025

From Instil Bio

Via GlobeNewswire

Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

January 14, 2025

From Instil Bio

Via GlobeNewswire

TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024 ↗

August 13, 2024

TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023 ↗

March 21, 2024

TIL stock results show that Instil Bio beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside ↗

January 07, 2025

Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments.

Via Benzinga

Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 13, 2024

From Instil Bio

Via GlobeNewswire

Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? ↗

October 24, 2024

This drugmaker's lead candidate could become a top-selling cancer therapy.

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 08, 2024

Via Benzinga

2 Stocks Up Over 700% in 2024 That Could Soar Even Further ↗

September 25, 2024

These relatively small companies are developing new cancer therapies that could generate billions in annual sales.

Via The Motley Fool

TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023 ↗

December 13, 2023

TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2023.

Via InvestorPlace

Steelcase Reports Weak Sales, Joins American Healthcare REIT And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

September 19, 2024

Via Benzinga

Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

September 17, 2024

Via Benzinga

Here's Why Everyone's Talking About Summit Therapeutics ↗

September 17, 2024

Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.

Via The Motley Fool

Crude Oil Surges Over 1%; Instil Bio Shares Plunge ↗

September 16, 2024

Via Benzinga

iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

September 16, 2024

Via Benzinga

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

September 16, 2024

From Instil Bio

Via GlobeNewswire

Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? ↗

September 14, 2024

A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy.

Via The Motley Fool

Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday ↗

September 12, 2024

Via Benzinga

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 13, 2024

From Instil Bio

Via GlobeNewswire

Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal ↗

August 03, 2024

Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million,...

Via Talk Markets

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

August 01, 2024

From Instil Bio

Via GlobeNewswire

Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

July 12, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

July 12, 2024

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Via InvestorPlace

TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024 ↗

May 10, 2024

TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 10, 2024

From Instil Bio

Via GlobeNewswire

Instil Bio Announces Strategic Update

January 16, 2024

From Instil Bio

Via GlobeNewswire

TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023 ↗

December 13, 2023

TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2023.

Via InvestorPlace

TIL Stock Earnings: Instil Bio Misses EPS for Q3 2023 ↗

December 13, 2023

TIL stock results show that Instil Bio missed analyst estimates for earnings per share the third quarter of 2023.

Via InvestorPlace

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.